An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48-Weeks in Subjects Who Have Completed 96 -Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018.
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2014
At a glance
- Drugs Elvucitabine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Achillion Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 21 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2008 New trial record.